Is Cannabis Legal in Italy?

The Legal Framework

Italy's drug control system is governed by Presidential Decree 309/1990, known as the Testo Unico sulle droghe — a consolidated statute that classifies drugs into tables and sets out penalties across the spectrum of possession, cultivation, supply, and trafficking. Cannabis sits in Table I as a substance under strict control, alongside other narcotics and psychotropics.

The 1990 decree has been amended significantly over the decades. A 1993 referendum removed criminal penalties for personal possession, replacing them with administrative sanctions. A 2006 law under the Berlusconi government reversed some of these protections, treating light drugs (including cannabis) and heavy drugs more similarly. A subsequent Constitutional Court ruling in 2014 struck down elements of the 2006 reform, reinstating more differentiated treatment between cannabis and harder substances.

The current framework therefore distinguishes between personal possession — which triggers administrative sanctions such as suspension of the driving licence, passport, or other government-issued documents for one to three months — and quantities that exceed what is considered consistent with personal use, for which criminal prosecution for trafficking becomes possible. The definition of personal use is not fixed in law by grams; it is assessed by prefectural authorities and prosecutors on a case-by-case basis using indicative guidelines, which critics argue creates uneven enforcement.

Cannabis Light: Italy's Unique Grey Market

Perhaps no aspect of Italy's cannabis landscape has attracted more commercial attention — or more legal uncertainty — than the cannabis light sector. Following a 2016 law (Law 242/2016) designed to promote the cultivation of industrial hemp in Italy, a market emerged rapidly for low-THC cannabis products sold in dedicated shops and online. These products — dried flower, pre-rolls, oils, resins — typically contain THC at or below 0.5%, exploiting a technical reading of the 2016 law's agricultural framework.

By 2019, an estimated 1,000 cannabis light shops had opened across Italy, with major cities like Milan, Rome, and Turin seeing significant concentrations. The products are sold nominally as collector's items, for technical purposes, or for aromatherapy — a legal fiction that masked a market clearly oriented at adult consumers seeking a mild psychoactive or wellness product.

Contradictory Supreme Court Rulings

The Italian Supreme Court (Corte di Cassazione) has produced deeply contradictory jurisprudence on cannabis light. In May 2019, the United Sections of the Supreme Court ruled that cannabis light retail sales constituted drug trafficking under the Testo Unico, sending shockwaves through the sector and temporarily driving many retailers out of business. However, subsequent individual section rulings moved in the opposite direction, finding that products with THC below the legal threshold for psychoactive effect could not constitute narcotics under the decree.

This inconsistency has never been definitively resolved. Retailers and producers operate under a framework of legal ambiguity that has persisted into 2026. Law enforcement approach varies by region and municipality. For businesses active in this space, the risk profile is real: product seizures, shop closures, and prosecutorial investigations have continued intermittently even as the market has continued to function.

The Italian parliament has debated, but not enacted, legislation that would definitively clarify the status of cannabis light products. Any such clarification — either legitimising the sector with appropriate regulation or explicitly prohibiting it — would represent a material change to the current market structure.

Medical Cannabis

Italy has one of Europe's longer-standing medical cannabis programmes. Legislative Decree 219/2006 and subsequent ministerial decrees established the framework under which cannabis preparations can be prescribed, initially limited and requiring case-by-case authorisation. Further reforms in 2013 and 2015 broadened and simplified the prescribing framework, enabling standard prescriptions for a range of indications without individual patient exemptions.

What makes Italy's model structurally distinctive is the role of the state in production. The Military Chemical Pharmaceutical Institute (Istituto Chimico Farmaceutico Militare — IMFF) in Florence serves as the authorised domestic producer of medical cannabis under a ministerial mandate. This state monopoly model reflects Italy's historical approach to controlled medicines and was intended to ensure quality control and affordable supply independent of commercial pharmaceutical interests.

Prescribable Indications

Italian physicians can prescribe cannabis-based preparations for the following indications:

• Chronic pain where standard therapies have failed
• Spasticity associated with multiple sclerosis
• Nausea and vomiting induced by chemotherapy, radiotherapy, or HIV therapy
• Reduction of intraocular pressure in glaucoma refractory to standard treatment
• Loss of appetite and weight in patients with anorexia or cachexia
• Tourette's syndrome
• Post-traumatic stress disorder (PTSD)

This is a relatively broad prescribing basis by European standards, reflecting the programme's maturity. However, supply has been a persistent structural problem. The IMFF has not consistently produced sufficient volumes to meet demand, resulting in significant reliance on imports from the Netherlands (Bedrocan products) and Canadian producers. Supply shortages have periodically left patients without product, a situation that has driven repeated calls from patients and clinicians for expanded domestic production capacity and the licensing of private producers.

Reimbursement under the national health system (SSN) is not universal: some regions cover cannabis prescriptions, others do not, creating a postcode-lottery dynamic that disadvantages patients in less progressive health administrations. Out-of-pocket costs for non-reimbursed patients can be substantial.

Business Landscape

Italy presents a complex commercial picture. The medical cannabis market is growing but constrained by the state production monopoly and import dependency. Private cultivation licences for medical cannabis production do not exist under the current framework, leaving international operators unable to establish supply chains from Italian soil without a fundamental legislative change.

The cannabis light and hemp sectors represent the most commercially active parts of the market, albeit with the legal uncertainties described. Italy's hemp cultivation tradition is longstanding, and the country produces significant volumes of fibre hemp. The CBD extract and consumer product sectors have grown rapidly, tracking European trends, with the same regulatory ambiguities around Novel Food classification and product format.

International investors and operators watching Italy tend to focus on the medium-term potential: a country of 60 million people with a mature medical cannabis programme, demonstrated consumer demand for cannabis products, and a political environment that is currently restrictive but where the structural conditions for a broader regulatory framework exist. The trajectory matters more than the current position.

Penalties

• Personal possession (small amounts): Administrative sanctions — suspension of driving licence, passport, or firearms permit for one to three months. No criminal charge, no custodial sentence.
• Personal possession (larger amounts, presumed dealing): Criminal prosecution; courts assess intent and quantity. Threshold is not fixed by law.
• Illicit cultivation (personal scale): Courts have acquitted in some small-scale home cultivation cases; others have been prosecuted as trafficking. Highly fact-specific.
• Supply and trafficking (cannabis as a "light drug"): Two to six years imprisonment and a fine under DPR 309/1990 Article 73 (light drugs). Aggravated trafficking — organised crime, large quantities, sales to minors — carries significantly higher penalties.
• Cannabis light retail (contested): Where prosecutors apply the 2019 Supreme Court reasoning, seizures and trafficking charges have been brought. Where courts apply the later jurisprudence, acquittals have followed.

2026 Outlook

Italy's cannabis policy trajectory under the Meloni government points toward consolidation of existing frameworks rather than liberalisation. The centre-right coalition has expressed scepticism about cannabis reform, and the 2022 referendum failure removed the most likely near-term mechanism for change. Legislative proposals from opposition parties have not attracted sufficient cross-party support to advance.

The medical programme will continue to evolve. Pressure from patient organisations, prescribing clinicians, and the healthcare system itself is likely to push for expanded IMFF production capacity, broader reimbursement, and potentially — over a longer horizon — the licensing of private producers to address structural supply gaps. Any movement on private production licences would represent the most commercially significant development in the Italian market.

The cannabis light sector's legal status is the most volatile variable. A definitive parliamentary resolution — in either direction — would reshape the market materially. Absent such resolution, the grey market will persist, with continued episodic enforcement creating an unstable operating environment for retailers and producers.

For European industry watchers, Italy's combination of a large consumer base, a functioning medical framework, and demonstrated popular demand for reform positions it as a significant medium-term market — one where the commercial and political conditions for broader change are gradually maturing, even if the current government's posture delays the timeline.